

Data Sheet

Product Name:	Brontictuzumab
Cat. No.:	CS-0620827
CAS No.:	1447814-75-6
Target:	Notch
Pathway:	Neuronal Signaling; Stem Cell/Wnt
Solubility:	10 mM in DMSO

Brontictuzumab

BIOLOGICAL ACTIVITY:

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma^{[1][2][3]}. *In Vitro*: Brontictuzumab (0-100 µg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity^[1]. Brontictuzumab (25 µg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line^[1]. Brontictuzumab (25 µg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells^[2]. Brontictuzumab (25 µg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells^[2]. *In Vivo*: Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft^[3]. Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model^[2].

References:

- [1]. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. *Ann Oncol.* 2018 Jul 1;29(7):1561-1568.
- [2]. Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. *J Exp Clin Cancer Res.* 2019 Nov 1;38(1):446.
- [3]. Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. *Leukemia.* 2014 Feb;28(2):278-88.

CAIndexNames:

Immunoglobulin G2 (human-Mus musculus monoclonal OMP-52M51 heavy chain), disulfide with human-Mus musculus monoclonal OMP-52M51 light chain, dimer

SMILES:

[Brontictuzumab]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA